Uncategorized

Russia’s Biosimilar Powerhouse: BIOCAD’s Patent Pipeline and the Oncology Disruption No One in the West Is Watching

Russia’s biosimilar story is no longer a footnote—it’s becoming a playbook. And if you’re in pharma, biotech, investing, or policy, the real risk isn’t that Russia will “catch up.” It’s that Russia is already building a pipeline designed to win on spee…

Russia’s Biosimilar Powerhouse: BIOCAD’s Patent Pipeline and the Oncology Disruption No One in the West Is Watching Read Post »

Biotechblog
Scroll to Top